Squarepoint’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Squarepoint’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-43,430	Closed	-$1M	–	3879
2020 Q4	$1M	Sell	43,430 -27,709	-39%	-$351K	0.01%	1332
2020 Q3	$724K	Buy	71,139 +17,280	+32%	+$232K	0.01%	1188
2020 Q2	$802K	Buy	53,859 +36,677	+213%	+$565K	0.01%	1065
2020 Q1	$209K	Sell	17,182 -2,972	-15%	-$47.3K	0.01%	1462
2019 Q4	$319K	Buy	+20,154	New	+$257K	﹤0.01%	2005

Squarepoint's PRVL Position: Q1 2021 in Review

Squarepoint sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 43,430 shares — an estimated $1M sold.

Squarepoint first reported a position in PRVL in Q4 2019 and held it in 5 quarters. The position peaked at $1M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Squarepoint reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 43,430 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1M.
Squarepoint first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Squarepoint's Prevail Therapeutics Inc. Common Stock position peaked at $1M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.